What if one short course of a strawberry-derived supplement could reverse frailty in breast cancer survivors after chemotherapy? Recent research is exploring whether fisetin could actually reverse frailty for breast cancer survivors.
New MOASC 2026 data shows how fisetin can reverse frailty in breast cancer survivors after chemo. At the MOASC 2026 Annual Meeting, Dr. Mina S. Sedrak, MD, MS, FASCO, Associate Professor of Medicine and Director of the UCLA Center for Cancer and Aging, presented Targeting Aging Biology to Improve the Health of Cancer Patients and Survivors.
For example, in an exclusive video interview (watch below), Dr. Sedrak breaks down the science of therapy-induced senescence. Moreover, she shares the first human-trial evidence that fisetin — a safe, natural senolytic — can improve physical function in survivors.
Video: Dr. Mina Sedrak on Fisetin, Frailty, and Cancer Survivorship
Caption: Dr. Mina Sedrak explains how therapy-induced senescence drives accelerated aging in cancer survivors and reveals new data from the PROFY and TROPHY trials showing that a short course of the senolytic fisetin can reverse frailty after chemotherapy. Filmed live at MOASC 2026.
Lifespan Up, Healthspan Down: The Urgent Need in Survivorship
Oncology has slashed cancer mortality. However, many survivors now face a new problem: accelerated aging.
In addition, Dr. Sedrak opened her MOASC talk with clear data. For example, U.S. life expectancy rose from 31 years in 1900 to 79 today. Yet healthy years without chronic disease average just 67 — leaving 11 years of illness. Therefore, chronic disease prevalence now hits 60 %.
As a result, survivors face excess morbidity and earlier onset of frailty, multimorbidity, and disability compared with the general population. Moreover, allogeneic transplant survivors show dramatically higher severe chronic conditions and frailty than their siblings.
Why Therapy-Induced Senescence Is the Hidden Driver
Cancer treatments (chemo, radiation, ADCs, CDK4/6 inhibitors, immunotherapy) trigger cellular senescence. This is a stress response that stops damaged cells from dividing.
However, when these senescent cells linger, they secrete the senescence-associated secretory phenotype (SASP). As a result, proinflammatory cytokines, growth factors, and matrix-degrading enzymes fuel chronic inflammation, tissue damage, and frailty.
Dr. Mina S. Sedrak explained, “Therapy-induced senescence is a central process which we think may be driving the accelerated aging phenotype that we see in our patients.”
Fisetin: From Preclinical Promise to Human Trials
Dr. Sedrak’s team chose fisetin — a natural flavonoid in strawberries, apples, and persimmons — for its excellent safety profile and proven senolytic activity in mice.
In addition, lab studies showed fisetin-rich diets reduced P16, P21, and SASP markers. Therefore, the mice also gained better grip strength, speed, endurance, and overall physical function.
That led directly to the PROFY and TROPHY trials. These are the first human studies of fisetin in breast cancer survivors after chemotherapy.
Primary endpoint: Change in 6-minute walk distance. This is a validated, CMS-approved test of physiologic reserve that correlates with VO2 max and real-world daily function.
As Dr. Sedrak noted, “We chose fisetin, which is a natural flavonoid, because of its really incredible safety profile, as well as the preclinical data to suggest that it has senolytic properties… We thought that that might represent a potential opportunity to begin to test our hypothesis that we could reverse or reduce some of the accelerated effects in humans.”
P16 (measurable in blood CD3+ T cells) is being explored as a biomarker of senescence burden. However, Dr. Sedrak notes more validation is still needed before it becomes routine.
How This Could Transform Long-Term Survivorship Care
Targeting the fundamental biology of aging — rather than just treating symptoms — could deliver real benefits. For example, it could restore physical function and quality of life. In addition, it could reduce chronic disease burden. Moreover, it might lower recurrence risk by disrupting SASP-driven tumor dormancy. Therefore, oncology can shift from tumor-only precision medicine to whole-patient care.
Dr. Sedrak emphasized: we must treat the person in whom the tumor resides, not just the tumor itself.
Key Takeaways from Dr. Sedrak’s MOASC 2026 Presentation
- Therapy-induced senescence is a modifiable driver of frailty in survivors.
- Fisetin shows early promise as a safe, short-course senolytic.
- The 6-minute walk test is a practical, patient-centered endpoint.
- P16 and other senescence biomarkers are under active development.
Can fisetin become standard supportive care? The PROFY and TROPHY results are a major step forward.
Related OncologyTube Resources:
- Can a Blood Test Detect Breast Cancer Recurrence Years Early?
- Survivorship After Breast Cancer: What Every Oncologist Needs to Know
What do you think? Could a natural senolytic like fisetin change how we support cancer survivors? Share your thoughts in the comments and subscribe for more cutting-edge research from OncologyTube.
Disclosure: No relevant financial disclosures reported by Dr. Sedrak for this presentation.
References
- Nat Rev Cancer. 2014;14:61–70
- Cell. 2023;186:243–278
- Nat Med. 2018;24:1246–1256
- Cancer. 2023;129:624–633
